Nelson-Aalen Cumulative Hazard Decomposition Reveals Hidden Failure Modes in Accelerated Stability Studies

When pharmaceutical companies design new protein-based drugs — like the antibodies and engineered proteins increasingly used to treat cancer or rare diseases — they need to know how long those drugs will stay stable on the shelf. Testing this at room temperature would take years, so labs use a shortcut: crank up the heat and watch the drug fall apart faster, then use chemistry math to predict what happens at normal storage temperatures. This is called accelerated stability testing, and it's been the industry standard for decades. The problem is that proteins don't fall apart in just one way. They can unfold like a crumpled piece of origami, get chopped up by enzymatic processes, clump together, or chemically degrade through oxidation. Each of these 'failure modes' is sensitive to heat in its own distinct way — some accelerate dramatically with temperature, others barely budge. So when you crank up the heat, you're not getting a fair, proportional speedup of real-world aging; you're getting a distorted picture where heat-sensitive failures look more important than they really are. The current approach lumps all these failure modes into a single number and extrapolates, which could lead to systematically wrong predictions. This hypothesis borrows a 200-year-old actuarial math technique — the kind used by life insurance companies to figure out what people die from and when — and applies it to protein drugs. By mathematically separating the contribution of each individual failure mode at each temperature, then extrapolating each one independently to real-world conditions, the approach could produce much sharper, more honest predictions of how long a drug will actually last in a refrigerator.

This is an AI-generated summary. Read the full mechanism below for technical detail.